These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17612852)

  • 41. Antidepressant-selective gynecomastia.
    Kaufman KR; Podolsky D; Greenman D; Madraswala R
    Ann Pharmacother; 2013 Jan; 47(1):e6. PubMed ID: 23324513
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials.
    Beesdo K; Hartford J; Russell J; Spann M; Ball S; Wittchen HU
    J Anxiety Disord; 2009 Dec; 23(8):1064-71. PubMed ID: 19643572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A case study of salami slicing: pooled analyses of duloxetine for depression.
    Spielmans GI; Biehn TL; Sawrey DL
    Psychother Psychosom; 2010; 79(2):97-106. PubMed ID: 20051707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Duloxetine: a new selective and dual-acting antidepressant.
    Bauer M; Möller HJ; Schneider E
    Expert Opin Pharmacother; 2006 Mar; 7(4):421-7. PubMed ID: 16503814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder.
    Dunner DL; Wilson M; Fava M; Kornstein S; Munoz R; O'Reardon J; Trivedi M; Wohlreich M
    Depress Anxiety; 2008; 25(5):E1-8. PubMed ID: 17621644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Desvenlafaxine: another "me too" drug?
    Sopko MA; Ehret MJ; Grgas M
    Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and tolerability of antidepressants: weighing the impact on treatment decisions.
    Schatzberg AF
    J Clin Psychiatry; 2007; 68 Suppl 8():26-34. PubMed ID: 17640155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis.
    Spielmans GI
    Psychother Psychosom; 2008; 77(1):12-6. PubMed ID: 18087203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Major depressive disorder, antidepressants, and sexual dysfunction.
    Clayton AH; Montejo AL
    J Clin Psychiatry; 2006; 67 Suppl 6():33-7. PubMed ID: 16848675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of duloxetine on primary pain symptoms in Parkinson disease.
    Djaldetti R; Yust-Katz S; Kolianov V; Melamed E; Dabby R
    Clin Neuropharmacol; 2007; 30(4):201-5. PubMed ID: 17762316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
    Fava M; Wiltse C; Walker D; Brecht S; Chen A; Perahia D
    J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response.
    Blier P
    J Psychiatry Neurosci; 2001; 26 Suppl(Suppl):S3-10. PubMed ID: 11590967
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
    Raskin J; Wiltse CG; Dinkel JJ; Walker DJ; Desaiah D; Katona C
    J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generalized tonic-clonic seizure secondary to duloxetine poisoning: a short report with favorable out come.
    Pellicciari A; Balzarro B; Scaramelli A; Porcelli S; Serretti A; De Ronchi D
    Neurotoxicology; 2012 Mar; 33(2):189-90. PubMed ID: 22306002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Major Depressive Disorder and HIV-1 Infection: A Review of Treatment Trials.
    Elliott AJ; Roy-Byrne PP
    Semin Clin Neuropsychiatry; 1998 Apr; 3(2):137-150. PubMed ID: 10085200
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Dual mechanism of action. Remission of physical symptoms].
    MMW Fortschr Med; 2005 May; 147 Spec No 2():87. PubMed ID: 15968881
    [No Abstract]   [Full Text] [Related]  

  • 59. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.
    Kamath J; Handratta V
    Expert Rev Neurother; 2008 Dec; 8(12):1787-97. PubMed ID: 19086875
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Duloxetine in the treatment of generalized anxiety disorder.
    Kornstein SG; Russell JM; Spann ME; Crits-Christoph P; Ball SG
    Expert Rev Neurother; 2009 Feb; 9(2):155-65. PubMed ID: 19210191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.